JP2018516566A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516566A5
JP2018516566A5 JP2017560327A JP2017560327A JP2018516566A5 JP 2018516566 A5 JP2018516566 A5 JP 2018516566A5 JP 2017560327 A JP2017560327 A JP 2017560327A JP 2017560327 A JP2017560327 A JP 2017560327A JP 2018516566 A5 JP2018516566 A5 JP 2018516566A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
enpp1
pharmaceutical composition
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560327A
Other languages
English (en)
Japanese (ja)
Other versions
JP6995627B2 (ja
JP2018516566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/033236 external-priority patent/WO2016187408A1/en
Publication of JP2018516566A publication Critical patent/JP2018516566A/ja
Publication of JP2018516566A5 publication Critical patent/JP2018516566A5/ja
Priority to JP2021202984A priority Critical patent/JP7390349B2/ja
Application granted granted Critical
Publication of JP6995627B2 publication Critical patent/JP6995627B2/ja
Priority to JP2023196352A priority patent/JP7778392B2/ja
Priority to JP2025191616A priority patent/JP2026015456A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017560327A 2015-05-19 2016-05-19 病的石灰化状態を治療するための組成物およびそれを使用する方法 Active JP6995627B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021202984A JP7390349B2 (ja) 2015-05-19 2021-12-15 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2023196352A JP7778392B2 (ja) 2015-05-19 2023-11-20 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2025191616A JP2026015456A (ja) 2015-05-19 2025-11-12 病的石灰化状態を治療するための組成物およびそれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163500P 2015-05-19 2015-05-19
US62/163,500 2015-05-19
PCT/US2016/033236 WO2016187408A1 (en) 2015-05-19 2016-05-19 Compositions for treating pathological calcification conditions, and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021202984A Division JP7390349B2 (ja) 2015-05-19 2021-12-15 病的石灰化状態を治療するための組成物およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2018516566A JP2018516566A (ja) 2018-06-28
JP2018516566A5 true JP2018516566A5 (enExample) 2019-06-20
JP6995627B2 JP6995627B2 (ja) 2022-02-04

Family

ID=57320640

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017560327A Active JP6995627B2 (ja) 2015-05-19 2016-05-19 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2021202984A Active JP7390349B2 (ja) 2015-05-19 2021-12-15 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2023196352A Active JP7778392B2 (ja) 2015-05-19 2023-11-20 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2025191616A Pending JP2026015456A (ja) 2015-05-19 2025-11-12 病的石灰化状態を治療するための組成物およびそれを使用する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021202984A Active JP7390349B2 (ja) 2015-05-19 2021-12-15 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2023196352A Active JP7778392B2 (ja) 2015-05-19 2023-11-20 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2025191616A Pending JP2026015456A (ja) 2015-05-19 2025-11-12 病的石灰化状態を治療するための組成物およびそれを使用する方法

Country Status (11)

Country Link
US (10) US10064917B2 (enExample)
EP (2) EP3298140B1 (enExample)
JP (4) JP6995627B2 (enExample)
KR (2) KR20250078598A (enExample)
AU (3) AU2016264364B2 (enExample)
CA (2) CA2984947A1 (enExample)
ES (1) ES2983910T3 (enExample)
MX (2) MX391074B (enExample)
PL (1) PL3298140T3 (enExample)
RU (2) RU2757417C2 (enExample)
WO (1) WO2016187408A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525780B1 (en) 2010-01-19 2022-09-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
PL2956163T3 (pl) 2013-02-13 2025-04-14 Yale University Kompozycje do leczenia patologicznego zwapnienia i kostnienia
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
HK1245662A1 (zh) * 2014-12-19 2018-08-31 Alexion Pharmaceuticals, Inc. 治疗组织钙化的方法
EP3298140B1 (en) * 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
EP3377105A4 (en) 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
JP2021523139A (ja) 2018-05-08 2021-09-02 イエール ユニバーシティ 腎石症の進行を遅らせるための組成物および方法
EP3844280A4 (en) * 2018-08-31 2022-09-14 Yale University ENPP1 POLYPEPTIDES AND METHODS OF USE
CN113631033B (zh) * 2019-01-18 2024-10-15 依诺兹梅制药公司 与enpp1或enpp3缺乏有关的疾病的治疗
CA3127256A1 (en) 2019-01-24 2020-07-30 Northwestern University High density lipoprotein mimetic nanoparticles using lipid conjugated core scaffolds
US20220195402A1 (en) * 2019-04-05 2022-06-23 Yale University Enpp1 polypeptides and methods of using same
KR20230048480A (ko) * 2020-05-27 2023-04-11 이노자임 파마, 인코포레이티드 말초 동맥 질환을 치료하기 위한 조성물 및 방법
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
WO2022076848A1 (en) * 2020-10-08 2022-04-14 Inozyme Pharma, Inc. Liver specific production of enpp1 or enpp3
KR20230123932A (ko) * 2020-11-19 2023-08-24 이노자임 파마, 인코포레이티드 Enpp1 결핍증 및 abcc6 결핍증의 치료
MX2024003506A (es) * 2021-09-24 2024-04-23 Inozyme Pharma Inc Formulaciones de polipéptidos enpp1 liofilizados y usos de estas.
EP4766376A1 (en) * 2023-08-22 2026-07-01 BioMarin Pharmaceutical Inc. TREATMENT OF ENPP1 AND ABCC6 DEFICIENCY IN CHILDREN
WO2025255052A1 (en) * 2024-06-03 2025-12-11 Inozyme Pharma, Inc. Treatment of enpp1 deficiency and abcc6 deficiency in infants
WO2026102337A1 (en) 2024-11-08 2026-05-15 Biomarin Pharmaceutical Inc. Enpp1 for use in the treatment of calciphylaxis

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
WO1995019570A1 (en) 1994-01-14 1995-07-20 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
WO2002092020A2 (en) 2001-03-23 2002-11-21 The Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
AU2002324700A1 (en) * 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
EP1537140B1 (en) 2001-11-07 2013-01-02 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
CA2610159C (en) 2005-06-10 2015-03-31 Altus Pharmaceuticals Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
PT2046373E (pt) 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
KR100986619B1 (ko) * 2010-03-12 2010-10-08 이상훈 이동통신단말기를 이용한 멀티입출력장치 및 방법
EP2545080B1 (en) 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
EP2683742B1 (en) * 2011-03-11 2018-12-19 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
PL2956163T3 (pl) * 2013-02-13 2025-04-14 Yale University Kompozycje do leczenia patologicznego zwapnienia i kostnienia
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
HK1245662A1 (zh) 2014-12-19 2018-08-31 Alexion Pharmaceuticals, Inc. 治疗组织钙化的方法
EP3298140B1 (en) * 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same

Similar Documents

Publication Publication Date Title
ES2906615T3 (es) Tratamiento derivado de citocinas con síndrome de fuga vascular reducido
US10562965B2 (en) Compositions and methods of use for treating metabolic disorders
JP6383122B2 (ja) Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
JP2018502836A5 (enExample)
RU2021129201A (ru) Композиции для лечения патологических состояний кальцификации и способы их применения
JP2024010052A (ja) 組織石灰化の治療方法
JP2010518079A5 (enExample)
EP2968483B1 (en) Subcutaneous administration of adamts13
JP2017518303A5 (enExample)
RU2017123540A (ru) Лечение судорог с использованием щелочной фосфатазы
JP2023027301A (ja) キメラ凝固因子を使用して血友病性関節症を処置する方法
CA2828504A1 (en) Antagonists of the interleukin-1 receptor
JP2018537093A5 (enExample)
US11299528B2 (en) Long acting TRAIL receptor agonists for treatment of autoimmune diseases
ES2883417T3 (es) Composiciones para su uso en el tratamiento o mejora de neuroinflamación, neurodegeneración, dolor neuropático y migraña
WO2015191997A1 (en) Anti-human chemokine (c-c motif) receptor 4 immunotoxins
WO2023154953A1 (en) Gdf15 polypeptides for treating and preventing autoimmune diseases
KR20240167914A (ko) Enpp1 결핍증 및 abcc6 결핍증의 치료
US20140296154A1 (en) Method of preventing development of psoriatic lesions
US20150366952A1 (en) Methods for reducing fibrosis induced by peritoneal dialysis
HK40112655A (en) Lyophilized enpp1 polypeptide formulations and uses thereof
US20250241983A1 (en) Non-opioid methods for treating pain
KR20260058843A (ko) 소아 enpp1 결핍증 및 abcc6 결핍증의 치료
TW202330017A (zh) 凍乾的enpp1多肽調配物及其用途
JPWO2018079701A1 (ja) ラクトフェリン活性を有するタンパク質を含む、抗ガン治療補助剤